ASPsiRNA ID | Pairing of target region (top) and ASP-siRNA (bottom) | Efficacy (mut)(%) | Efficacy (wt) (%) | Diff | Gene | Disease | Mutation | RefSNP | Analysis | Pubmed ID |
---|---|---|---|---|---|---|---|---|---|---|
ASPsiRNA ID | Mutant allele/ASP-siRNA | Efficacy for mutant(%) |
Efficacy for wild (%) |
Relative Difference (%) | Gene | Disease | Mutation | RefSNP | Analysis | Pubmed ID |
aspsirna0213 | GCAGAAGCACCAGGAAAGA CGUCUUCGUGGUCCUUUCU |
3 | 2 | 1 | SNCA | Parkinsons disease (PD) | c.88G>C,p.Ala30Pro | rs10489387 | ||
aspsirna0214 | CAGAAGCACCAGGAAAGAC GUCUUCGUGGUCCUUUCUG |
20 | 0 | 20 | SNCA | Parkinsons disease (PD) | c.88G>C,p.Ala30Pro | rs10489387 | ||
aspsirna0215 | AGAAGCACCAGGAAAGACA UCUUCGUGGUCCUUUCUGU |
10 | 12 | -2 | SNCA | Parkinsons disease (PD) | c.88G>C,p.Ala30Pro | rs10489387 | ||
aspsirna0216 | GAAGCACCAGGAAAGACAA CUUCGUGGUCCUUUCUGUU |
40 | 0 | 40 | SNCA | Parkinsons disease (PD) | c.88G>C,p.Ala30Pro | rs10489387 | ||
aspsirna0217 | AAGCACCAGGAAAGACAAA UUCGUGGUCCUUUCUGUUU |
14 | 0 | 14 | SNCA | Parkinsons disease (PD) | c.88G>C,p.Ala30Pro | rs10489387 | ||
aspsirna0218 | AGCACCAGGAAAGACAAAG UCGUGGUCCUUUCUGUUUC |
5 | 0 | 5 | SNCA | Parkinsons disease (PD) | c.88G>C,p.Ala30Pro | rs10489387 | ||
aspsirna0219 | GCACCAGGAAAGACAAAGA CGUGGUCCUUUCUGUUUCU |
20 | 15 | 5 | SNCA | Parkinsons disease (PD) | c.88G>C,p.Ala30Pro | rs10489387 | ||
aspsirna0220 | GCAGAAGCGCCAGGAAAGA CGUCUUCGCGGUCCUUUCU |
15 | 40 | -25 | SNCA | Parkinsons disease (PD) | c.88G>C,p.Ala30Pro | rs10489387 | ||
aspsirna0221 | CAGAAGCGCCAGGAAAGAC GUCUUCGCGGUCCUUUCUG |
26 | 40 | -14 | SNCA | Parkinsons disease (PD) | c.88G>C,p.Ala30Pro | rs10489387 | ||
aspsirna0222 | AGAAGCGCCAGGAAAGACA UCUUCGCGGUCCUUUCUGU |
46 | 40 | 6 | SNCA | Parkinsons disease (PD) | c.88G>C,p.Ala30Pro | rs10489387 | ||
aspsirna0223 | GAAGCGCCAGGAAAGACAA CUUCGCGGUCCUUUCUGUU |
15 | 38 | -23 | SNCA | Parkinsons disease (PD) | c.88G>C,p.Ala30Pro | rs10489387 | ||
aspsirna0224 | GAGCGCCAGGAAAGACAAA CUCGCGGUCCUUUCUGUUU |
80 | 22 | 58 | SNCA | Parkinsons disease (PD) | c.88G>C,p.Ala30Pro | rs10489387 | ||
aspsirna0225 | AGCGCCAGGAAAGACAAAG UCGCGGUCCUUUCUGUUUC |
10 | 27 | -17 | SNCA | Parkinsons disease (PD) | c.88G>C,p.Ala30Pro | rs10489387 | ||
aspsirna0226 | GCGCCAGGAAAGACAAAAG CGCGGUCCUUUCUGUUUUC |
80 | 70 | 10 | SNCA | Parkinsons disease (PD) | c.88G>C,p.Ala30Pro | rs10489387 | ||
aspsirna0227 | GCAGAAGCACCAGGAAAGA CGUCUUCGUGGUCCUUUCU |
10 | 2 | 8 | SNCA | Parkinsons disease (PD) | c.88G>C,p.Ala30Pro | rs10489387 | ||
aspsirna0228 | CAGAAGCACCAGGAAAGAC GUCUUCGUGGUCCUUUCUG |
20 | 10 | 10 | SNCA | Parkinsons disease (PD) | c.88G>C,p.Ala30Pro | rs10489387 | ||
aspsirna0229 | AGAAGCACCAGGAAAGACA UCUUCGUGGUCCUUUCUGU |
30 | 15 | 15 | SNCA | Parkinsons disease (PD) | c.88G>C,p.Ala30Pro | rs10489387 | ||
aspsirna0230 | GAAGCACCAGGAAAGACAA CUUCGUGGUCCUUUCUGUU |
40 | 10 | 30 | SNCA | Parkinsons disease (PD) | c.88G>C,p.Ala30Pro | rs10489387 | ||
aspsirna0231 | AAGCACCAGGAAAGACAAA UUCGUGGUCCUUUCUGUUU |
50 | 10 | 40 | SNCA | Parkinsons disease (PD) | c.88G>C,p.Ala30Pro | rs10489387 | ||
aspsirna0232 | AGCACCAGGAAAGACAAAG UCGUGGUCCUUUCUGUUUC |
5 | 0 | 5 | SNCA | Parkinsons disease (PD) | c.88G>C,p.Ala30Pro | rs10489387 | ||
aspsirna0233 | GCACCAGGAAAGACAAAGA CGUGGUCCUUUCUGUUUCU |
70 | 15 | 55 | SNCA | Parkinsons disease (PD) | c.88G>C,p.Ala30Pro | rs10489387 | ||
aspsirna0234 | GCAGAAGCGCCAGGAAAGA CGUCUUCGCGGUCCUUUCU |
15 | 40 | -25 | SNCA | Parkinsons disease (PD) | c.88G>C,p.Ala30Pro | rs10489387 | ||
aspsirna0235 | CAGAAGCGCCAGGAAAGAC GUCUUCGCGGUCCUUUCUG |
45 | 40 | 5 | SNCA | Parkinsons disease (PD) | c.88G>C,p.Ala30Pro | rs10489387 | ||
aspsirna0236 | AGAAGCGCCAGGAAAGACA UCUUCGCGGUCCUUUCUGU |
46 | 40 | 6 | SNCA | Parkinsons disease (PD) | c.88G>C,p.Ala30Pro | rs10489387 | ||
aspsirna0237 | GAAGCGCCAGGAAAGACAA CUUCGCGGUCCUUUCUGUU |
40 | 38 | 2 | SNCA | Parkinsons disease (PD) | c.88G>C,p.Ala30Pro | rs10489387 | ||
aspsirna0238 | GAGCGCCAGGAAAGACAAA CUCGCGGUCCUUUCUGUUU |
80 | 30 | 50 | SNCA | Parkinsons disease (PD) | c.88G>C,p.Ala30Pro | rs10489387 | ||
aspsirna0239 | AGCGCCAGGAAAGACAAAG UCGCGGUCCUUUCUGUUUC |
38 | 25 | 13 | SNCA | Parkinsons disease (PD) | c.88G>C,p.Ala30Pro | rs10489387 | ||
aspsirna0240 | GCGCCAGGAAAGACAAAAG CGCGGUCCUUUCUGUUUUC |
70 | 60 | 10 | SNCA | Parkinsons disease (PD) | c.88G>C,p.Ala30Pro | rs10489387 | ||
aspsirna0241 | GCAAAGAUUGCUGACUACA CGUUUCUAACGACUGAUGU |
75 | 27 | 48 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0242 | CAAAGAUUGCUGACUACAG GUUUCUAACGACUGAUGUC |
40 | 20 | 20 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0243 | GAAGAUUGCUGACUACAGC CUUCUAACGACUGAUGUCG |
60 | 24 | 36 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0244 | GAGAUUGCUGACUACAGCA CUCUAACGACUGAUGUCGU |
2 | 55 | -53 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0245 | AGAUUGCUGACUACAGCAU UCUAACGACUGAUGUCGUA |
13 | 88 | -75 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0246 | GAUUGCUGACUACAGCAUU CUAACGACUGAUGUCGUAA |
13 | 59 | -46 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0247 | AUUGCUGACUACAGCAUUG UAACGACUGAUGUCGUAAC |
40 | 27 | 13 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0248 | UUGCUGACUACAGCAUUGC AACGACUGAUGUCGUAACG |
30 | 20 | 10 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0249 | UGCUGACUACAGCAUUGCU ACGACUGAUGUCGUAACGA |
55 | 50 | 5 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0250 | GCUGACUACAGCAUUGCUC CGACUGAUGUCGUAACGAG |
75 | 30 | 45 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0251 | CUGACUACAGCAUUGCUCA GACUGAUGUCGUAACGAGU |
60 | 40 | 20 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0252 | UGACUACAGCAUUGCUCAG ACUGAUGUCGUAACGAGUC |
80 | 65 | 15 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0253 | GACUACAGCAUUGCUCAGU CUGAUGUCGUAACGAGUCA |
60 | 45 | 15 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0254 | ACUACAGCAUUGCUCAGUA UGAUGUCGUAACGAGUCAU |
77 | 65 | 12 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0255 | CUACAGCAUUGCUCAGUAC GAUGUCGUAACGAGUCAUG |
80 | 60 | 20 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0256 | UACAGCAUUGCUCAGUACU AUGUCGUAACGAGUCAUGA |
50 | 40 | 10 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0257 | CUGAUUACAGCAUUGCUCA GACUAAUGUCGUAACGAGU |
36 | 10 | 26 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0258 | CUGAGUACAGCAUUGCUCA GACUCAUGUCGUAACGAGU |
88 | 73 | 15 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0259 | ACUACAGCACUGCUCAGUA UGAUGUCGUGACGAGUCAU |
76 | 45 | 31 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0260 | ACUACAGCAGUGCUCAGUA UGAUGUCGUCACGAGUCAU |
88 | 25 | 63 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0261 | ACUAUAGCAUUGCUCAGUA UGAUAUCGUAACGAGUCAU |
62 | 24 | 38 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0262 | ACUAGAGCAUUGCUCAGUA UGAUCUCGUAACGAGUCAU |
67 | 49 | 18 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0263 | CUAUAGCAUUGCUCAGUAC GAUAUCGUAACGAGUCAUG |
50 | 21 | 29 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0264 | CUAGAGCAUUGCUCAGUAC GAUCUCGUAACGAGUCAUG |
30 | 25 | 5 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0265 | CUGACUACAGUAUUGCUCA GACUGAUGUCAUAACGAGU |
72 | 60 | 12 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0266 | CUGACUACAGGAUUGCUCA GACUGAUGUCCUAACGAGU |
46 | 65 | -19 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0267 | CUGACUACAGAAUUGCUCA GACUGAUGUCUUAACGAGU |
85 | 55 | 30 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0268 | CUGACUACAACAUUGCUCA GACUGAUGUUGUAACGAGU |
70 | 56 | 14 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0269 | CUGACUACAUCAUUGCUCA GACUGAUGUAGUAACGAGU |
88 | 60 | 28 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0270 | CUGACUACACCAUUGCUCA GACUGAUGUGGUAACGAGU |
7 | 16 | -9 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0271 | GAGAUUGCUGGCUACAGCA CUCUAACGACCGAUGUCGU |
92 | 15 | 77 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0272 | GAGAUUGCUAACUACAGCA CUCUAACGAUUGAUGUCGU |
75 | 5 | 70 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 | ||
aspsirna0273 | GAGAUUGCGGACUACAGCA CUCUAACGCCUGAUGUCGU |
55 | 30 | 25 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 |